Aurobindo Pharma ties up with Gilead

RELATED NEWS Gilead inks licensing pacts with 4 Indian firms Aurobindo Pharma bets on low-cost strengths Aurobindo receives approval in Citalopram oral solution ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 25/05/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo Pharma Ltd has announced that it has entered into an agreement with the US-based pharma major Gilead Sciences to manufacture and market generic versions of their anti-retroviral brand Viread (Tenofovir disoproxil fumerate) in 95 countries under the Gilead access programme.

In a press release here on Tuesday, the company said the country's classification is rated according to the Human Development index and includes high prevalence focus countries in Africa and Asia, including India. According to the company, the licensing agreements with Gilead Sciences include a technology transfer to enable expeditious production of large volumes of high quality generic version of Tenofovir DF.

Taken from Business Line

thehindubusinessline.in